Foghorn Therapeutics Inc. (FHTX) News
Track canonical SquawkNews coverage tagged to FHTX, Foghorn Therapeutics Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Foghorn Therapeutics Stock Plummets as Eli Lilly Partnership Ends on Cancer Drug
Foghorn Therapeutics (FHTX) shares dropped nearly 45% in pre-market trading after announcing it would discontinue the development of its experimental cancer drug FHD-909, a move made under its partnership with Eli Lilly
EQUITY | Oct 01, 2026, 01:24 PM UTC
H
Foghorn Therapeutics to Cut 40% of Workforce After Drug Discontinuation
Foghorn Therapeutics will cut 40% of its workforce after discontinuing its experimental cancer drug, which was partnered with Eli Lilly. The drug failed to show sufficient benefit in an early-stage trial, and the compani
EQUITY | Oct 01, 2026, 12:11 PM UTC
M
Foghorn Therapeutics Ends Lilly Cancer Drug Trials, Cuts 40% Workforce
Foghorn Therapeutics and Eli Lilly will discontinue joint development of their lead oncology candidate due to disappointing Phase 1 trial results. Foghorn will also reduce its workforce by approximately 40%. Foghorn shar
EQUITY | Oct 01, 2026, 11:40 AM UTC
M
Foghorn Therapeutics Reports Q2 Financials
Foghorn Therapeutics releases Q2 financial update
EQUITY | Aug 06, 2026, 11:00 AM UTC